Welcome to Anavex Life Sciences Corp. Our Precision Medicine platform encompasses novel small molecule treatments designed to address some of the most challenging central nervous system (CNS) diseases facing society today, including Alzheimer’s disease, Parkinson’s disease, Schizophrenia and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome. We believe that targeting the upstream Sigma-1 receptor (SIGMAR1), through our proprietary orally available compounds, previously developed within the SIGMACEPTOR™ discovery platform, have the capability to unlock the body’s own defenses to potentially treat CNS conditions. Following the completion of several promising clinical trials, we are progressing into a clinical stage and are starting to explore community engagement with the aim to potentially provide benefit for patients across the globe and ensure access to our new CNS treatment paradigm.
Our Dedication
Our product portfolio platform is inspired by the lived experiences of the people living with neurodegenerative and neurodevelopmental disorders and the strength and dedication of carers.
​​​
​
​
​
​
​
​
​
​
Autophagy
The activation of SIGMAR1 by ANAVEX®2-73 (Blarcamesine) presents a scalable potential therapeutic solution for Alzheimer's disease (AD) by countering neurodegeneration and improving autophagy. Blarcamesine has demonstrated in-vivo ability to improve elderly immune systems by making cells more able to clear out their waste, in a process called autophagy enhancement. Autophagy is a key clearance mechanism that removes protein aggregates and misfolded proteins.
​​
SIGMAR1
Our proprietary SIGMACEPTOR™ platform produces orally available therapeutic candidates that lead to the modulation of SIGMAR1. Data suggests that activation of SIGMAR1 results in the restoration of upstream compensatory activities within the body, pivotal to neural cell homeostasis and neuroplasticity.
​
​
​
​
​
​
News
Autophagy through SIGMAR1 Activation
Orally administered ANAVEX®2-73 (blarcamesine) is a novel, investigational small molecule that activates an upstream compensatory process. Blarcamesine is a scalable potential therapeutic solution for Alzheimer’s disease by countering neurodegeneration and improving autophagy – a key clearance mechanism that removes protein aggregates and misfolded proteins.
*Blarcamesine is an investigational drug that is not available for sale and has not been determined to be safe and effective by any regulatory authority.